Skip to main content

Advertisement

Table 1 Baseline and follow-up characteristics of the study population

From: HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection

  HD# MEU HCV HIV/HCV P-value
Number 22 8 21 23  
General characteristics      
 Gender, n male (%) * 7 (87.5) 15 (71.4) 14 (60.9) 0.36
 Western ethnicity, n (%) * 8 (100.0) 21 (100.0) 19 (82.6) 0.13
 Ever injected drugs, n (%) * 8 (100.0) 21 (100.0) 23 (100.0) 1.00
 Years of injecting (IQR) * 6.7 (6.1–13.6) 13.4 (5.4–19.6) 9.0 (6.4–14.6) 0.20
Baseline (T = 1)      
 Age, median (IQR) 36.4 (31.5–40.1) 32.8 (28.7–35.2) 34.4 (30.7–37.5) 35.2 (32.6–39.8) 0.30
 Sample since study entry * 12.7 (0–47.6) 12.6 (1.7–31.7) 14.7 (0–25.8) 0.98
 (months), median (IQR)      
 Year of sample, * 1992 (1989–1994) 1992 (1990–1994) 1991 (1989–1993) 0.43
 median (IQR)      
 Injecting past 6 months(%) * 1 (12.5) 14 (66.7) 16 (73.9) 0.07
 CD 4 cell counts 106 cells/L, * * * 590 (470–742) *
 median (IQR)      
 cART, n (%) * * * 1 (4.5) *
Follow-up (T = 2)      
 Age, median (IQR) 52.7 (48.3–57.6) 51.7 (49.2–54.8) 51.7 (47.4–55.5) 50.4 (47.7–54.2) 0.97
 Injecting past 6 months (%) * 1 (12.5) 4 (19.0) 4 (17.9) 0.92
 CD 4 cell counts 106 cells/L, * * * 341 (233–663) *
 median (IQR)      
 cART, n (%) * * * 20 (87.0) *
 Years on cART, median (IQR) * * * 7.1 (2.1–10.7) *
  1. cART combination anti-retroviral therapy, HCV Hepatitis C virus, HD Healthy donor, IQR Interquartile range, MEU Multiple exposed but uninfected with HCV or HIV
  2. #HD at T = 1 and T = 2 are not the same individuals; * Data unavailable